Accompanied by Zerbach & Company Corporate Finance GmbH ("Z&C"), Cannaveg Pharma GmbH, Oldenburg ("Cannaveg"), has taken two southern German entrepreneurial families into its circle of shareholders as part of a financing round, who will support the company's further growth over the long term.
Cannaveg is an independent wholesaler in the field of medical cannabis and exclusively imports medical cannabis to the highest quality standards and GMP certification for distribution through selected pharmacies.
After advising the family office PHK Enterprise on its investment in DEMECAN, the only German producer of medical cannabis, in 2020, this is already the second successful transaction of Zerbach & Company in the still young German cannabis market.
The capital raised will be used to expand the existing business in the medical cannabis sector as well as to broaden activities in preparation for the upcoming legalization of cannabis for recreational purposes in Germany.
Dr. Lars Junc, Partner in charge at Zerbach & Company, explains: "We are very pleased that we were able to make an important contribution to the further successful growth of Cannaveg with our industry experience and our investor network, and we thank the entire team for the good cooperation."
